



International Prostate Cancer Symposium  
Where translational research meets therapeutic innovation

# IPCS 2026

# Poster Exhibition

# Programme

28-29 April 2026  
Palazzo dei Congressi, Lugano, Switzerland

 [www.apccc.org/ipcs](http://www.apccc.org/ipcs)

IPCS 2026 is organised by the Foundation for the Institute of Oncology Research (IOR) in collaboration with APC Society, with the support of

**AAGR** American Association  
for Cancer Research®  
FINDING CURES TOGETHER™

**EAU** European  
Association  
of Urology



# IPCS 2026

## Poster Exhibition Programme

**Opens on Tuesday 28 April at 16:00**

**Wednesday 29 April 2026  
12:30-14:00 Poster Session**

**Room B2 - First floor - Convention Centre**

IPCS 2026 is organised by the Foundation for the Institute of Oncology Research (IOR) in collaboration with APC Society, with the support of



Poster Nr.	Title and Presenter	Presentation Format
<b>Category: Molecular Biology and Genetics</b>		
1	Elucidating the role of DNA-dependent dimerization for androgen receptor signaling <b>Peperstraete Kaat</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
2	Epithelial cell-intrinsic role of SOCS1 in maintaining prostate tissue homeostasis, attenuating inflammation and reducing susceptibility to carcinogenesis <b>Ilangumaran Subburaj</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
3	Decoding the Complexity of Prostate Cancer Evolution: Uncovering Heterogeneous Cell States by Cutting-Edge Integrative Approaches <b>Cassanmagnago Giada Andrea</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
4	From Reconstruction to Resolution: Platform Approaches to Engineer the Prostate Cancer Phenoscape and Map Its Evolution <b>Bezzi Marco</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
5	Chronic Circadian Disruption Promotes Neuroendocrine Prostate Cancer Pathogenesis <b>Huang Weichao</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
6	Prostate cancer-derived extracellular vesicles promote GDF15 <sup>+</sup> immunoregulatory macrophage polarization within the tumor microenvironment <b>Mazumdar Alekhya</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
7	Drosophila accessory gland: a tool to unveil and understand the molecular program of resistance. <b>de Jossineau Cyrille</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
8	A Quality By Design-Based Approach For Screening of Ingredients and Optimization of Formulation For Prostate Cancer <b>Vasu Peddinti</b>	Poster Exhibition - B2

9	Compensating Transcription Factors in Treatment-Induced Cellular Plasticity and Adaptive Resistance in Advanced Prostate Cancer <b>Dekker Witteke</b>	Poster Exhibition - B2
10	PARP supports intratumor immature neutrophil expansion in cancer <b>Maddalena Martino</b>	Poster Exhibition - B2
11	Targeting Pre-Existing Club-Like Cells in Prostate Cancer Potentiates Androgen Deprivation Therapy <b>Goffin Vincent</b>	Poster Exhibition - B2
12	From AR+ to AR- : STING signaling and hormone therapy-induced lineage plasticity in prostate cancer <b>Van Goubergen Jasper</b>	Poster Exhibition - B2
13	Adipocyte-derived androgens: role in progression and castration resistance of prostate cancer at the primary and bone metastatic site <b>Lacombe Mathilde</b>	Poster Exhibition - B2
14	CRISPR screen reveals essential pathways that crosstalk with androgen receptor signaling in prostate cancer <b>Haendler Bernard</b>	Poster Exhibition - B2
15	An advanced 3D model of bone metastasis from castration-resistant prostate cancer reveals a vicious cycle of citrate and lactate and unveils a new therapeutic axis <b>Pasquarelli Alessandro</b>	Poster Exhibition - B2
16	Genome-wide CRISPR screen in prostate cancer cells reveals drivers of macrophage-mediated cell kill <b>Zaalberg Anniek</b>	Poster Exhibition - B2
17	Single-cell analysis uncovers preserved prostate cancer lineages and universally altered pathways in Matrigel-free patient-derived organoids <b>Dolgos Robin</b>	Poster Exhibition - B2
18	SWI/SNF Dependency as a Druggable Driver of Lineage Plasticity in Castration-Resistant Prostate Cancer <b>Paassen Irene</b>	Poster Exhibition - B2

19	Investigating the role of therapy-induced senescence in the development of prostate cancer bone metastases within a human in vitro model of bone <b>Dziri Imen</b>	Poster Exhibition - B2
20	ARMUK: a tool for the integration of user's knowledge in the mining of frequent patterns and association rules in cancer genomics <b>Michel Sara</b>	Poster Exhibition - B2
21	FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment <b>Yu Jindan</b>	Poster Exhibition - B2
22	Targeting ERG oncogenic activation with an intracellular mini-antibody in TMPRSS2:ERG fusion-positive prostate cancer. <b>Musumeci Carola</b>	Poster Exhibition - B2
23	Role of AR-FOXA1 composite element in chromatin landscaping of highrisk prostate cancer <b>Willems Hanne</b>	Poster Exhibition - B2
26	DNA methylation across prostate cancer disease states <b>Lise Stefano</b>	Poster Exhibition - B2
27	PRC2 subunit AEBP2 is a prognostic marker in metastatic prostate cancer <b>Takala Eerika</b>	Poster Exhibition - B2
28	YAP/TAZ Signalling is Prognostic and Negatively Associated with AR Activity in Prostate Cancer <b>Schlag Anna</b>	Poster Exhibition - B2

## Category: Diagnostics & Biomarkers

29	Immuno-metabolic phenotypes in metastatic hormone-sensitive prostate cancer (mHSPC): post-hoc analysis of the ENZAMET trial (ANZUP 1304) <b>Horvath Lisa</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
30	Non-invasive prostate cancer subtyping using 5hmC-sequencing of cellfree DNA. <b>Sjöström Martin</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
31	High-throughput circulating proteome for non-invasive identification of clinically significant prostate cancer <b>Ostano Paola</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
32	Building Movember-SAiGENCI-Transformational Integrated Repository (MSTIR): A global database to enable clinical and biomarker discovery in prostate cancer care <b>McKeown Sam</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
33	Prognostic value of circulating CD11b+CD33+ myeloid cells in localized prostate cancer <b>Moscarda Viola</b>	Poster Exhibition - B2
34	Transcriptome-wide classifiers for clinical stratification of high-risk locally advanced prostate cancer <b>Howlett Sarah</b>	Poster Exhibition - B2
35	Comprehensive AI analysis of prostatectomy slides reveals poor representation of immune heterogeneity in core biopsies <b>Fittall Matthew</b>	Poster Exhibition - B2
36	Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy for Non-Metastatic High-Risk Prostate Cancer in Two STAMPEDE Phase 3 Trials <b>Grist Emily</b>	Poster Exhibition - B2
37	NMR-based metabolomics to differentiate clinically insignificant from clinically significant prostate cancer: Interim results of the prospective multicenter PROSPIN trial <b>Ladurner Michael</b>	Poster Exhibition - B2

38	Association between air pollution exposure and the incidence, progression, and prognosis of prostate cancer: Evidence from multiple cohort studies <b>Zeng Bin</b>	Poster Exhibition - B2
39	Association and Causal Verification Between Clonal Hematopoiesis of Indeterminate Potential and Prostate Cancer Risk: A Large-Scale Population-Based Study <b>Zhou Xianghong</b>	Poster Exhibition - B2
40	Survival outcomes following PSMA PET/CT staging in unfavourable intermediate-risk prostate cancer <b>Damiani Sara</b>	Poster Exhibition - B2
41	Identification of circulating and tissue biomarkers to predict early biochemical recurrence in intermediate grade prostate cancer patients <b>Peraldo Neia Caterina</b>	Poster Exhibition - B2
42	Circulating tumour DNA and outcome in stereotactic body radiotherapy treated oligoprogressing metastatic castration-resistant prostate cancer patients in the TRAP trial <b>Wetterskog Daniel</b>	Poster Exhibition - B2
43	PSMA-PET tumor volume risk stratifies non-metastatic castration-resistant prostate cancer <b>Civan Caner</b>	Poster Exhibition - B2
44	Prognostic role of PSMA PET/CT in intermediate-risk prostate cancer patients <b>Guglielmo Priscilla</b>	Poster Exhibition - B2
45	ProClass: A gene expression-based classifier for predicting recurrence in localized prostate cancer post-prostatectomy, independent of intraand interfocal heterogeneity <b>Skotheim Rolf</b>	Poster Exhibition - B2
46	From focality to fusions: Towards improved risk stratification and personalised treatment for prostate cancer patients <b>Kidd Susanne Gundersen</b>	Poster Exhibition - B2
47	Impact of germline and somatic BRCA alterations on the progression patterns of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) by disease volume <b>Villarrubia Jorge Esteban</b>	Poster Exhibition - B2

48	Plasma-based assessment of microsatellite instability in metastatic castration-resistant prostate cancer using the PCF_SELECT targeted capture panel <b>Chan Sylvie</b>	Poster Exhibition - B2
49	Systemic myeloid signatures and S100A12 predict poor prognosis in metastatic prostate cancer and reflect tumor-induced inflammation in preclinical models <b>Lundholm Marie</b>	Poster Exhibition - B2
50	Integrated proteomic profiling of prostate cancer extracellular vesicles across tissue, plasma, and urine identifies matrix-specific and metastasis-associated signatures <b>Constâncio Vera</b>	Poster Exhibition - B2
<b>Category: Therapeutic resistance</b>		
51	Intracellular osteopontin dictates the release of TNF $\alpha$ by mast cells to restrain neuroendocrine prostate cancer <b>Jachetti Elena</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
52	Novel patient-derived organoid xenograft models reveal molecular and clinical trajectories of prostate cancer progression <b>Parmentier Romuald</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
53	When Senescence Backfires: The Role of B Cells in PCa Progression <b>Colucci Manuel</b>	Poster Exhibition - B2
54	Mast cells shape tumor cell metabolism to restrain treatment-related neuroendocrine prostate cancer <b>Scialpi Giuseppina Beatrice</b>	Poster Exhibition - B2
56	JMJD6 impact on prostate cancer: revealing a new epigenetic pathway driving neuroendocrine differentiation <b>Pinna Valeria</b>	Poster Exhibition - B2

### Category: Novel treatments

57	Restoring the PTEN Tumor Suppressor Axis: Small-Molecule Inhibition of the WWP1/WWP2 E3 Ligases <b>Sgrignani Jacopo</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
58	In silico discovery of potent small molecule inhibitors targeting the AR N-Terminal Domain for treating castration-resistant prostate cancer <b>Soldati Sasha &amp; Gamba Elia</b>	Poster Exhibition - B2
59	Development of novel [18F] FDG-PSMA hybrid PET tracer <b>Gredičak Matjia</b>	Poster Exhibition - B2
60	CDK9 inhibition promotes broad transcriptomic and phenotypic changes in prostate cancer reversing the imbalance in tricarboxylic acid cycle metabolism <b>Federici Elisa</b>	Poster Exhibition - B2
62	Development of a Soluble Compound Targeting Mitochondrial Complex I for Prostate Cancer Treatment – A Photosensitizer for PDT Application in Precision Treatment <b>Thi Thuy Le</b>	Poster Exhibition - B2
63	Exploration of Indane Scaffold Antagonists for combination prostate cancer therapy with cold Atmospheric Plasma <b>Zhang Shengxin</b>	Poster Exhibition - B2

### Category: Clinical Trials

64	Biological determinants of prostate cancer response to neoadjuvant hormone therapy <b>Ismail Mazlina</b>	Poster Exhibition - B2 Poster Flash - B1 Wed. 14:00-14:30
----	---	---